US 12,435,111 B2
Mutant VSV ectodomain polypeptide and uses thereof
Aurélie Albertini, Gometz le Chatel (FR); Hélène Raux, Antony (FR); Yves Gaudin, Paris (FR); and Franck Perez, Paris (FR)
Assigned to CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), Paris (FR); and UNIVERSITE PARIS SACLAY, Gif sur Yvette (FR)
Appl. No. 17/439,166
Filed by CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), Paris (FR); and UNIVERSITE PARIS SACLAY, Gif sur Yvette (FR)
PCT Filed Mar. 16, 2020, PCT No. PCT/EP2020/057144
§ 371(c)(1), (2) Date Sep. 14, 2021,
PCT Pub. No. WO2020/187850, PCT Pub. Date Sep. 24, 2020.
Claims priority of application No. 19305317 (EP), filed on Mar. 15, 2019.
Prior Publication US 2022/0162266 A1, May 26, 2022
Int. Cl. C07K 14/005 (2006.01); C12N 15/86 (2006.01)
CPC C07K 14/005 (2013.01) [C12N 15/86 (2013.01); C12N 2760/20222 (2013.01); C12N 2760/20243 (2013.01)] 19 Claims
 
1. A mutant polypeptide comprising the amino acid sequence of the ectodomain of glycoprotein G of a Vesicular stomatitis virus (VSV) strain, wherein said ectodomain comprises the amino acid sequence of SEQ ID NO:2 or an amino acid sequence having at least 90% identity with the amino acid sequence of SEQ ID NO:2, with at least one substitution of an amino acid residue selected from the group consisting of:
a) the amino acid residue located at position 422 of SEQ ID NO:2;
b) the amino acid residue located at position 22 of SEQ ID NO:2;
c) any amino acid residue located at position equivalent to position 422 of SEQ ID NO:2 after optimal global alignment with SEQ ID NO:2 and
d) any amino acid residue located at a position equivalent to position 22 of SEQ ID NO:2, after optimal global alignment with SEQ ID NO:2.